Please login to the form below

Not currently logged in
Email:
Password:

Rydapt

This page shows the latest Rydapt news and features for those working in and with pharma, biotech and healthcare.

Astellas, Catalyst approvals set up record year for FDA approvals

Astellas, Catalyst approvals set up record year for FDA approvals

It is the second drug in the FLT3 inhibitor class to be approved in the US after Novartis’ Rydapt (midostaurin), which was approved for newly-diagnosed FLT3-positive AML by the

Latest news

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics